Article Text
Paper
Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases
Abstract
This paper deals with the question of how to price drugs for tropical diseases. The thesis defended in the paper is: (i) there should be no legal constraints on the profits pharmaceutical companies can make on their products for tropical diseases. In essence, (i) expresses the idea that drugs for tropical diseases should be treated as any other product on the free market and that the producers of these drugs should be allowed to sell their products at whatever price the market can bear. The main argument in favour of (i) is first outlined. Five common arguments against (i) are thereafter discussed, and it is argued that all of these fail in their intended purpose.
Statistics from Altmetric.com
Linked Articles
- The concise argument
Read the full text or download the PDF:
Other content recommended for you
- Should rare diseases get special treatment?
- Patent pools: an idea whose time has come
- Don’t worry about the drug industry’s profits when considering a waiver on covid-19 intellectual property rights
- US incentive scheme for neglected diseases: a good idea gone wrong?
- New deal from the World Trade Organisation
- Ethical issues in funding research and development of drugs for neglected tropical diseases
- Public sector financial support for late stage discovery of new drugs in the United States: cohort study
- Ethical issues in funding orphan drug research and development
- Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most
- Prioritising neglected diseases related to poverty